Is the new bivalent COVID-19 vaccine the booster we’ve been waiting for?

The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.

Distinct gut bacteria identified in octogenarians linked to aging and health

Research reveals unique gut bacteria in Singaporean seniors, highlighting the microbiome’s role in promoting healthier aging and reducing chronic disorders.

September 11, 2024

Biohacking: Unlocking the Future of Optimal Health

Biohacking, the practice of leveraging lifestyle health technologies to optimize physical and mental well-being, is gaining significant traction as people increasingly prioritize their health and wellness.

June 9, 2023

Amylyx to voluntarily withdraw ALS drug Relyvrio after Phase 3 fail, will lay off around 70%

Amylyx announced Thursday morning that it will pull its ALS drug Relyvrio from the US and Canadian markets. The decision comes as Amylyx will also

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.